SEC Form 3 · accession 0001214659-18-006856
NEXIEN BIOPHARMA, INC. · NXEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeremy Robert Reeh
Officer — VP Translational Research
Period of report
Oct 26, 2018
Accepted (ET)
Nov 2, 2018 · 5:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001625288
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 1,925,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F130% of the shares will be released from forfeiture restrictions beginning October 26, 2019 and on each of the next two anniversaries.